GLP-1 Medications, Fatty Liver and Weight Loss: What the Science Shows
Medications such as Ozempic®, Wegovy®, Mounjaro® and Zepbound® are increasingly used to support weight loss and improve metabolic health. These medications belong to a class of treatments known as incretin-based therapies.
Incretins are natural gut hormones released after eating that help regulate appetite, insulin secretion, and blood glucose levels. Two of the most important incretin hormones are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).
Weight-loss injections such as semaglutide (Ozempic®, Wegovy®) act as GLP-1 receptor agonists, meaning they mimic the action of the natural GLP-1 hormone. Newer medications such as tirzepatide (Mounjaro®, Zepbound®) activate both GLP-1 and GIP receptors, providing dual incretin activity.
While these medications are widely recognised for their ability to reduce appetite and support significant weight loss, research is increasingly showing they may also have important effects on liver health and metabolic disease.
A review by Newsome and Ambery explores how incretin therapies influence liver metabolism and their potential role in managing metabolic liver disease.
Understanding Incretins
Incretins are hormones released from the gastrointestinal tract following food intake. Their primary role is to enhance insulin secretion from pancreatic β-cells in a glucose-dependent manner, helping regulate blood glucose levels after meals.
The two key incretin hormones are:
• GLP-1 (Glucagon-like peptide-1)
• GIP (Glucose-dependent insulinotropic polypeptide)
Beyond insulin regulation, these hormones influence several metabolic processes including:
Appetite regulation via the brain’s satiety centres
Gastric emptying
Lipid metabolism
Energy balance
Pharmacological incretin therapies mimic or enhance these hormonal pathways to improve metabolic outcomes.
The Liver and Metabolic Disease
The liver plays a central role in metabolic homeostasis. It regulates:
Glucose production and storage
Lipid metabolism
Cholesterol synthesis
Hormonal signalling
In individuals with obesity or insulin resistance, excess fat can accumulate in the liver. This condition is now known as Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), previously referred to as non-alcoholic fatty liver disease (NAFLD).
MASLD is strongly associated with:
Type 2 diabetes
Obesity
Dyslipidaemia
Increased cardiovascular risk
How GLP-1 and Incretin Therapies Affect the Liver
According to the review by Newsome and Ambery, incretin-based therapies may influence liver health through multiple metabolic mechanisms.
Reduction in Liver Fat
Weight loss achieved through GLP-1 receptor agonists can significantly reduce hepatic steatosis (fat accumulation in the liver). Even moderate weight reduction is associated with measurable improvements in liver fat and metabolic markers.
Improved Insulin Sensitivity
GLP-1 therapies improve insulin secretion and suppress inappropriate glucagon release. Improved glycaemic control reduces metabolic stress on the liver and may reduce hepatic fat production.
Effects on Lipid Metabolism
Incretin signalling can influence lipid metabolism through several pathways including:
Reduced hepatic lipogenesis (fat production)
Increased fatty acid oxidation
Reduced ectopic fat deposition
These mechanisms may contribute to improvements in metabolic liver disease.
Potential Direct Hepatic Effects
While many of the benefits appear related to weight loss and improved metabolic control, researchers are also investigating direct hepatic signalling pathways influenced by incretin therapies, including effects on inflammation, fibrosis and cellular metabolism.
Dual and Triple Incretin Therapies
Newer medications are being developed to target multiple incretin receptors simultaneously.
Examples include:
Dual GLP-1/GIP agonists
Triple agonists targeting GLP-1, GIP and glucagon pathways
These therapies aim to enhance metabolic signalling and may produce greater weight loss and improved metabolic outcomes.
Ongoing clinical trials are exploring whether these therapies may also provide additional benefits for metabolic liver disease and cardiovascular risk reduction.
Why Nutrition Support Is Still Essential
Although GLP-1 and incretin-based medications are powerful tools for weight management, nutrition remains a critical component of treatment.
Because these medications suppress appetite, some individuals may unintentionally consume insufficient protein, fibre or micronutrients.
Appropriate nutritional support helps:
Preserve lean muscle mass during weight loss
Prevent micronutrient deficiencies
Support metabolic and liver health
Improve long-term weight maintenance
A structured nutrition approach ensures that weight loss occurs in a way that supports overall metabolic health rather than simply reducing calorie intake.
Final Thoughts
Incretin-based therapies represent a significant advancement in the treatment of obesity, type 2 diabetes and metabolic disease. As highlighted in the research by Newsome and Ambery, their effects extend beyond appetite regulation to include important influences on liver metabolism and metabolic health.
As these therapies continue to evolve, combining medical treatment with personalised nutrition support remains essential for achieving safe, sustainable and metabolically healthy weight loss.
References
Newsome, P. N., & Ambery, P. (2024).
Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver.
Journal of Hepatology.
Drucker, D. J. (2023).
Mechanisms of Action and Therapeutic Application of GLP-1.
Cell Metabolism.
Wilding, J. P. H., et al. (2021).
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
New England Journal of Medicine.
Jastreboff, A. M., et al. (2022).
Tirzepatide Once Weekly for the Treatment of Obesity.
New England Journal of Medicine.
